What FUJIFILM North America does

FUJIFILM North America operates as the regional arm of FUJIFILM Holdings Corporation (TSE: 4901), a Japanese diversified technology conglomerate originally founded in 1934 as Fuji Photo Film Co., Ltd. and reorganized under a holding-company structure in 2006. The Fujifilm Group reported ¥3,357.0 billion in revenue and employed 73,526 people globally as of March 31, 2026, operating across four segments: Healthcare (medical imaging systems, SYNAPSE medical IT, Bio-CDMO contract development and manufacturing services for biopharmaceuticals, and NURA health screening centers), Electronics (high-purity semiconductor process chemicals, photoresists, and display materials such as TAC films and EXCLEAR sensor films), Business Innovation (multifunction printers, production printers, DocuWorks, and the FUJIFILM IWpro cloud service delivered through channel partners globally), and Imaging (INSTAX instant cameras and film, X Series and GFX Series mirrorless cameras, Frontier digital minilabs, and LTO tape data storage media).

The company's technological backbone rests on proprietary materials chemistry, high-precision coating, and high-precision forming capabilities developed over 90 years and applied across otherwise distinct verticals. Fujifilm monetizes through a hybrid revenue model: hardware sales dominate Healthcare, Electronics, and consumer Imaging; subscription/recurring revenue underpins Business Innovation's managed document services and cloud offerings; and managed services drive the NURA health screening business. Go-to-market combines direct enterprise sales for medical imaging and semiconductor materials, a global channel-partner network for Business Innovation following the 2021 rebrand of Fuji Xerox to FUJIFILM Business Innovation, and retail/e-commerce plus app-store distribution for consumer imaging products. Geographic reach spans 18+ countries with primary markets in Japan, the US, Europe, China, India, and other parts of Asia.

Growth is anchored by the VISION2030 plan targeting ~35% revenue growth and 15%+ operating margin by 2030, with Bio-CDMO revenues targeted to triple and electronic materials targeted to grow at 2x the semiconductor sector. Capital allocation has been acquisitive, with major deals including Hitachi's diagnostic imaging business (2021) and Entegris' high-purity process chemicals business (2023). NURA health screening is the most visible frontier expansion, currently at 8 centers across India, Mongolia, and Vietnam with a stated goal of 100 locations by FY2030.

Name

FUJIFILM North America

Legal name

FUJIFILM Holdings Corporation

Website

https://fujifilm.com

Company type

Public

Founded year

1934

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

FUJIFILM North America is the regional arm of FUJIFILM Holdings Corporation (TSE: 4901), selling healthcare imaging systems, bio-CDMO services, semiconductor and display materials, office document solutions, and consumer imaging products to enterprise and consumer customers across the U.S. and Canada.

Ownership category

akta.pro rank

Product category

Diversified Imaging and Healthcare Technology

NAICS

Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Audio and Video Equipment Manufacturing (3343), Computer and Electronic Product Manufacturing (334), Surgical and Medical Instrument Manufacturing (339112)

SIC

Surgical & Medical Instruments & Apparatus (3841), Photographic Equipment & Supplies (3861), Electronic & Other Electrical Equipment (No Computer Equip) (3600)

akta.pro primary industry

X-ray & Fluoroscopy Systems (HLAHABAA)

akta.pro secondary industries

Universal Viewers & Enterprise Imaging Access (Zero-footprint/Diagnostic) (HLACALAD), Electrical & Electronics Film/Sheet Extrusion (Insulating Films, Display/Optical Films) (IMANACAE), Photo & Video Output Devices (Printers, Portable Photo Printers, Photo Frames) (CRACAPAL)

Keywords

• Diagnostic imaging equipment
• Biopharmaceutical contract manufacturing
• Semiconductor process chemicals
• Instant photography products
• Office document solutions

Headquarters

HQ city

Valhalla

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare: Healthcare segment includes medical systems (diagnostic imaging), bio-CDMO (contract manufacturing of biopharmaceuticals), and life sciences solutions. Accounts for approximately one-third of group revenue. The segment focuses on prevention, diagnosis, and treatment across medical设备, AI diagnostics, and drug development/manufacturing services.
2. Imaging: Consumer and professional imaging products including digital cameras (X Series, GFX Series), INSTAX instant cameras and printers, and photographic printing services. Maintains 20%+ profit margins, the highest across group businesses.
3. Electronics: Electronic materials including semiconductor process chemicals, display materials (sensor films, TAC films), and other materials for electronics manufacturing. Supports semiconductor production across Japan, US, Taiwan, Korea, and Belgium.
4. Business Innovation: Office solutions (document-related services including multifunction printers), business solutions (systems integration, cloud services, business process outsourcing), and graphic communications (print and digital media). Formerly Fuji Xerox, rebranded to FUJIFILM Business Innovation.
5. NURA Health Screening Services: Health check-up center services in emerging countries providing cancer and lifestyle disease screenings using Fujifilm's medical devices and AI technology. Operating in India, Mongolia, and Vietnam with expansion planned to 100 locations by FY2030.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

FUJIFILM North America operates across four business segments: Healthcare (medical imaging systems such as X-ray, CT, MRI, SYNAPSE medical IT platform, Bio-CDMO contract development and manufacturing services for biopharmaceuticals, and NURA health screening centers); Electronics (high-purity semiconductor process chemicals, photoresists, and display materials such as TAC films and sensor films); Business Innovation (multifunction printers, production printers, document management, and FUJIFILM IWpro cloud service for digital transformation); and Imaging (INSTAX instant cameras and film, X Series and GFX Series digital cameras, and LTO tape data storage media).

Product overview

FUJIFILM Corporation operates across four business segments: Healthcare, Electronics, Business Innovation, and Imaging. The Healthcare segment includes Medical Systems (diagnostic imaging equipment, SYNAPSE medical imaging IT platform), Bio-CDMO contract development and manufacturing services for biopharmaceuticals, and LS Solutions (life sciences). The Electronics segment covers Semiconductor Materials (high-purity process chemicals for wafer fabrication) and Display Materials (TAC films, touch panel sensor films). The Business Innovation segment encompasses FUJIFILM Business Innovation office solutions including multifunction printers, production printers, and the FUJIFILM IWpro cloud service for enterprise digital transformation. The Imaging segment includes Consumer Imaging (INSTAX instant cameras and film, photo printing services) and Professional Imaging (X Series and GFX Series mirrorless digital cameras, LTO tape data storage). NURA health screening centers represent a key healthcare service combining AI-powered diagnostic imaging with cancer and lifestyle disease screening in emerging markets.

Differentiator

Problem solved

Functional benefit

Brands

• INSTAX: Instant camera and printer brand including INSTAX mini, INSTAX SQUARE, and INSTAX WIDE product lines
• NURA
• instax
• X Series
• GFX Series
• SYNAPSE

Products and services

• NURA Health Screening Centers Health check-up centers operating in emerging countries that use Fujifilm AI-powered diagnostic imaging equipment including CT scanners and mammography systems to screen for cancer and lifestyle diseases, with results delivered by doctors viewing actual diagnostic images. Currently operating in India, Mongolia, and Vietnam with target of 100 locations by FY2030.
• SYNAPSE Medical Imaging and Information Management System

Quantifiable outcome

• 77,000+ people screened at NURA health centers
• +5 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• Union for International Cancer Control (UICC) / World Cancer DayflagshipStrategic or Co-development Partner · 1 January 2024Fujifilm partnered with World Cancer Day, a global initiative led by UICC, starting in 2024 and continuing as a 'Visionary Partner' from 2025 to 2027. The partnership supports patients, caregivers, and healthcare professionals while advancing Fujifilm's mission to make cancer prevention, detection, and treatment accessible to all. United by unique stories of resilience and hope, both organizations are committed to reducing the global cancer burden and improving patient outcomes through collaboration and innovation.
• Entegris (High-Purity Process Chemicals Business Acquisition)coreTechnology or Integration · 1 January 2023Fujifilm's 2023 acquisition of Entegris' high-purity process chemicals business expanded its product coverage to nearly all stages of semiconductor production. This acquisition strengthened Fujifilm's position as a comprehensive electronic materials supplier for semiconductor manufacturers.
• Hitachi, Ltd. (Diagnostic Imaging Business)coreTechnology or Integration · 1 March 2021Fujifilm acquired Hitachi, Ltd.'s diagnostic imaging business division in March 2021, expanding its healthcare segment capabilities. Given the high growth potential of the healthcare field, this acquisition strengthened Fujifilm's comprehensive healthcare offerings.
• Dr. Kutty's Healthcare (India)coreStrategic or Co-development Partner · 1 January 2021Fujifilm's key partner company in the health screening service business in India. Based in Kerala, which is the birthplace of the partnership. Dr. Kutty's Healthcare has produced many outstanding medical professionals who serve around the world, and the collaboration focuses on establishing NURA health screening centers in emerging countries.
• Various Emerging Market Healthcare PartnerscoreStrategic or Co-development Partner · 1 January 2021Business partners for operating NURA health screening centers in India, Mongolia, and Vietnam. Centers are equipped with Fujifilm's medical devices including CT scan and mammography systems, as well as medical IT systems based on AI technology designed to support doctors in conducting screenings for cancer and lifestyle diseases.
• Biogen (Denmark) Manufacturing ApScoreStrategic or Co-development Partner · 1 January 2019Fujifilm made Biogen's Danish manufacturing subsidiary a consolidated subsidiary in 2019 to further enhance its life sciences business and Bio-CDMO manufacturing capacity.
• Cellular Dynamics International, Inc. (USA)coreStrategic or Co-development Partner · 1 January 2015Fujifilm acquired this US-based company, a leader in the development and production of induced pluripotent stem cells (iPSCs), strengthening its drug discovery support and cell therapy field capabilities.

Scale indicators11 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Canon: Canon is a direct peer across Fujifilm's imaging (cameras), business innovation (printers), and healthcare (Canon Medical Systems) segments. Both companies compete in medical diagnostic imaging, consumer/professional cameras, and office multifunction printers with similar B2B and B2C go-to-market models.
• Siemens Healthineers: Siemens Healthineers is a direct peer in medical diagnostic imaging and laboratory diagnostics. Both compete across X-ray, CT, MRI, and enterprise imaging IT in hospital procurement globally.
• Lonza Group: Lonza is a direct peer in biopharmaceutical contract development and manufacturing (CDMO). Both companies compete for biopharma customers seeking mammalian cell culture, microbial fermentation, and biologics manufacturing capacity — directly relevant to Fujifilm's Bio-CDMO 3x growth target.
• Konica Minolta: Konica Minolta is a direct peer in office printing/imaging (multifunction printers, production print) and healthcare (digital radiography, medical imaging IT). Both companies share similar film-to-digital transformation histories and overlapping enterprise customer bases.
• Nikon: Nikon is a direct peer in professional and consumer cameras (Z Series mirrorless) and optical instruments (FUJINON vs NIKKOR lenses). Both companies compete for professional photographer and enthusiast camera customers globally.
• GE HealthCare: GE HealthCare is a direct peer in medical imaging equipment (CT, MRI, X-ray, ultrasound) and healthcare IT. Both companies sell diagnostic imaging systems into hospitals and compete for the same procurement budgets.
• Sony Group: Sony is a direct peer in consumer and professional imaging (Alpha mirrorless cameras, sensors) and competes with Fujifilm's X Series and GFX lines for professional photographer and content creator customers.
• Philips: Philips is a direct peer in diagnostic imaging (X-ray, CT, MRI, ultrasound) and healthcare informatics. Both vendors target similar hospital and clinical customer segments with overlapping imaging and patient monitoring portfolios.
• Ricoh: Ricoh is a direct peer in office printing, multifunction devices, and document workflow solutions. Both compete in the same enterprise channel partner ecosystem for office productivity and digital transformation deals.

Emerging players

• Samsung Biologics: Samsung Biologics is an emerging player in the global Bio-CDMO market, rapidly scaling mammalian cell culture capacity. As a newer entrant with aggressive capacity expansion, it is comparable to Fujifilm's Bio-CDMO growth ambitions but competes primarily in late-stage and commercial biologics manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/user/FUJIFILMglobal
• Facebookfacebook.com/FujifilmGlobal
• LinkedInlinkedin.com/company/fujifilm-north-america-corporation
• Instagraminstagram.com/fujifilmxworld
• Xx.com/fujifilmus

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FUJIFILM North America